Lininger R A, Park W S, Man Y G, Pham T, MacGrogan G, Zhuang Z, Tavassoli F A
Department of Gynecologic and Breast Pathology, The Armed Forces Institute of Pathology, Washington, DC 20306-6000, USA.
Hum Pathol. 1998 Oct;29(10):1113-8. doi: 10.1016/s0046-8177(98)90422-1.
Papillary carcinoma of the breast is a variant of predominantly intraductal carcinoma characterized by a papillary growth pattern with fibrovascular support. Loss of heterozygosity (LOH) was evaluated at multiple chromosomal loci (including loci reported to show frequent genetic alterations in breast cancer) to determine the frequency of genetic mutations in these tumors and their precursors. Thirty-three papillary lesions of the breast (6 papillary carcinomas, 12 carcinomas arising in a papilloma, and 15 intraductal papillomas with florid epithelial hyperplasia) were retrieved from the files of the Armed Forces Institute of Pathology (AFIP). Tumor cells and normal tissue were microdissected in each case and screened for LOH at INT-2 and p53 as well as several loci on chromosome 16p13 in the TSC2/PKD1 gene region (D16S423, D16S663, D16S665). LOH on chromosome 16p13 was present in 10 of 16 (63%) informative cases of either papillary carcinoma or carcinoma arising in a papilloma as well as in 6 of 10 (60%) informative cases of intraductal papilloma with florid epithelial hyperplasia (IDH). One case showed simultaneous LOH in both the florid IDH and carcinoma components of a papilloma. LOH was not observed at either INT-2 or p53 in any of the papillary carcinomas or papillomas with florid IDH. In conclusion, a high frequency of LOH at chromosome 16p13 (the TSC2/PKD1 gene region) is in both papillary carcinomas of the breast as well as in papillomas with florid IDH, including a case with LOH present simultaneously in both components. These findings suggest that chromosome 16p contains a tumor suppressor gene that frequently is mutated early in papillary neoplasia.
乳腺乳头状癌是一种主要为导管内癌的变体,其特征为具有纤维血管支持的乳头状生长模式。通过评估多个染色体位点(包括据报道在乳腺癌中显示频繁基因改变的位点)的杂合性缺失(LOH),以确定这些肿瘤及其前体中基因突变的频率。从武装部队病理研究所(AFIP)的档案中检索出33例乳腺乳头状病变(6例乳头状癌、12例起源于乳头状瘤的癌以及15例伴有显著上皮增生的导管内乳头状瘤)。对每个病例的肿瘤细胞和正常组织进行显微切割,并在INT-2和p53以及TSC2/PKD1基因区域(D16S423、D16S663、D16S665)的16p13染色体上的几个位点筛查LOH。在16例有信息的乳头状癌或起源于乳头状瘤的癌病例中,有10例(63%)存在16p13染色体上的LOH,在10例有信息的伴有显著上皮增生的导管内乳头状瘤(IDH)病例中,有6例(60%)存在该现象。1例病例显示在乳头状瘤的显著IDH和癌成分中同时存在LOH。在任何乳头状癌或伴有显著IDH的乳头状瘤中,均未在INT-2或p53处观察到LOH。总之,乳腺乳头状癌以及伴有显著IDH的乳头状瘤中,16p13染色体(TSC2/PKD1基因区域)上的LOH频率较高,包括1例在两个成分中同时存在LOH的病例。这些发现表明,16号染色体p区含有一个肿瘤抑制基因,该基因在乳头状肿瘤形成早期经常发生突变。